| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.46 M USD | -6.80 M USD | 27.88 M USD | -5.22 M USD | 10.75 M USD | 1.29 M USD | 1.78 M USD | 3.49 M USD | 1.24 M USD | 1.06 M USD | 2.10 M USD | 1.68 M USD |
| Depreciation & Amortization | 55.93 M USD | 57.12 M USD | 54.72 M USD | 49.32 M USD | 6.27 M USD | 4.07 M USD | 2.72 M USD | 1.88 M USD | 1.68 M USD | 1.56 M USD | 1.41 M USD | 1.60 M USD |
| Stock-Based Compensation | 6.03 M USD | 6.74 M USD | 7.84 M USD | 24.20 M USD | 1.79 M USD | 540000 USD | 278000 USD | 134000 USD | 19000 USD | 45000 USD | 79000 USD | 84000 USD |
| Capital Expenditures | 16.61 M USD | 22.31 M USD | 27.50 M USD | 36.30 M USD | 12.47 M USD | 6.20 M USD | 6.88 M USD | 1.32 M USD | 347000 USD | 1.26 M USD | 1.47 M USD | 490000 USD |
| Cash Flow from Investing | -12.89 M USD | -16.83 M USD | -28.75 M USD | -333.72 M USD | -54.06 M USD | -10.13 M USD | -8.15 M USD | -8.07 M USD | -339000 USD | -1.26 M USD | -1.43 M USD | -490000 USD |
| Cash Flow from Financing | 23.70 M USD | 9.68 M USD | 15.87 M USD | 203.15 M USD | 198.83 M USD | 9.64 M USD | 6.21 M USD | 4.93 M USD | -849000 USD | 144000 USD | -1.21 M USD | -1.51 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -27.07 M USD | -29.11 M USD | 380000 USD | -41.52 M USD | -1.73 M USD | -4.91 M USD | -5.10 M USD | 2.17 M USD | 889000 USD | -196000 USD | 637000 USD | 1.19 M USD |
Inotiv Inc. is a prominent company specializing in contract research organization (CRO) services primarily aimed at enhancing drug discovery and development. The primary function of Inotiv is to provide comprehensive non-clinical and analytical services for pharmaceutical and biotechnology industries. These services play a critical role in the early stages of drug development, supporting the transition from discovery through clinical trials by ensuring safety and efficacy standards are met. Notably, Inotiv Inc. is involved in toxicology and pathology studies, bioanalysis, and consulting, all of which are crucial in advancing pharmaceutical research. The company’s significance in the market lies in its ability to streamline the drug development process for clients, potentially accelerating the timeline for bringing new therapies to market. Given the ever-evolving nature of medical research, Inotiv stands as a vital partner for clients seeking to navigate the complex regulatory environment while driving innovation in therapeutic solutions. Headquartered in the United States, Inotiv Inc. operates in one of the most dynamic sectors of the healthcare industry, supporting a global clientele with high-impact scientific expertise.